Zeria Pharmaceutical (4559) · FactAdvanced
Measurement and Disclosure of Greenhouse Gas Emissions
First written in FY2025. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
GHG Emissions and Climate Change Metrics Disclosure PolicyA theme 23 companies write about · 0 as a headwind · 13 as a tailwind
10 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 23 companies compared. The sentences above are computed from all 23.Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「Following the absorption-type merger of our former subsidiary 健創製薬株式会社 on 1 April 2025, the number of plants owned by the company became 3, namely the Saitama Plant, Tsukuba Plant and Second Tsukuba Plant, formerly 健創製薬株式会社's Tsukuba Plant. Accordingly, the plants included in the greenhouse gas emissions calculation are as follows. …Scope 1 and 2 total 10,290 12,271」
Following the absorption-type merger of 健創製薬, the emissions reporting boundary was expanded to 3 plants, and combined Scope 1 and Scope 2 emissions were disclosed as 10,290 t-CO2 for fiscal 2024 and 12,271 t-CO2 for fiscal 2025. - FY2025First statedAnnual report
「Our greenhouse gas emissions were as follows. The reporting boundary was ゼリア新薬工業 on a standalone basis. (Unit: t-CO2) Scope 1 4,562 Scope 2 5,728 Scope 1 and 2 total 10,290」
Fiscal 2024 Scope 1 and Scope 2 emissions were disclosed for the first time as standalone data points, using the standalone company as the reporting boundary.